Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
50–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male
Aged 50 years or older
A diagnostic claim of benign prostatic hyperplasia (International Classification of Diseases, Ninth Revision, Clinical Modification \[ICD-9-CM\] codes 222.2x or 600.xx)
A prescription claim for a 5-alpha reductase inhibitor (5ARI) for at least 60 days during the observation period
Continuous health plan eligibilitiy for 6 months prior to and at least 150 days after the initial 5ARI prescription
You may not be if
A diagnosis of prostate cancer (ICD-9-CM codes 185.xx, 198.82, 233.4, 236.5, 239.5, V10.46)
A diagnosis of bladder cancer (ICD-9-CM codes 188.xx, 198.1, 223.3, 233.7, 239.4, V10.51),
A procedure code for any prostate-related surgery prior to the index date or 150 days after the index date
A diagnosis code for acute urinary retention (AUR) prior to the index date or 150 days after the index date